Minibody: A novel engineered anti-carcinoembryonic antigen antibody fragment (single-chain Fv-CH3) which exhibits rapid, high-level targeting of xenografts.

A novel engineered antibody fragment (VL-VH-CH3, or "minibody") with bivalent binding to carcinoembryonic antigen (CEA) was produced by genetic fusion of a T84.66 (anti-CEA) single-chain antibody (scFv) to the human IgG1 CH3 domain. Two designs for the connecting peptide were evaluated. In the T84.66/212 LD minibody, a two-amino acid linker (generated by fusion of restriction sites) was used to join VH and CH3. In the T84.66/212 Flex minibody, the human IgG1 hinge plus an additional 10 residues were used as the connecting peptide. Size exclusion chromatography of purified minibodies demonstrated that both proteins had assembled into Mr80,000 dimers as expected. Furthermore, analysis by SDS-PAGE under nonreducing conditions was consistent with disulfide bond formation in the hinge of the T84.66 Flex minibody. Purified minibodies retained high affinity for CEA (KA, 2 x 10(9) M(-1)) and demonstrated bivalent binding to antigen. Tumor targeting properties were evaluated in vivo using athymic mice bearing LS174T human colon carcinoma xenografts. 123I-labeled T84.66 minibodies demonstrated rapid, high tumor uptake, reaching 17% injected dose/gram (%ID/g) for the LD minibody and 33%ID/g for the Flex minibody at 6 h following injection. Radioiodinated minibody also cleared rapidly from the circulation, yielding high tumor:blood uptake ratios: 44.5 at 24 h for the LD minibody and 64.9 at 48 h for the Flex minibody. Rapid localization by the T84.66/212 Flex minibody allowed imaging of xenografts at 4 and 19 h after administration.

[1]  M. Little,et al.  Recombinant single-chain Fv fragments carrying C-terminal cysteine residues: production of bivalent and biotinylated miniantibodies. , 1994, Molecular immunology.

[2]  T Prospero,et al.  "Diabodies": small bivalent and bispecific antibody fragments. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[3]  T. Yokota,et al.  Construction, binding properties, metabolism, and tumor targeting of a single-chain Fv derived from the pancarcinoma monoclonal antibody CC49. , 1991, Cancer research.

[4]  J. Schlom,et al.  Secretion of a single-gene-encoded immunoglobulin from myeloma cells. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[5]  J. Deisenhofer Crystallographic refinement and atomic models of a human Fc fragment and its complex with fragment B of protein A from Staphylococcus aureus at 2.9- and 2.8-A resolution. , 1981, Biochemistry.

[6]  C. Chang,et al.  Analysis of immunoglobulin domain interactions. Evidence for a dominant role of salt bridges. , 1988, Journal of molecular biology.

[7]  J. Coligan,et al.  Isolation and characterization of carcinoembryonic antigen. , 1972, Immunochemistry.

[8]  J. Tso,et al.  Formation of a bispecific antibody by the use of leucine zippers. , 1992, Journal of immunology.

[9]  K. D. Hardman,et al.  An improved linker for single-chain Fv with reduced aggregation and enhanced proteolytic stability. , 1993, Protein engineering.

[10]  A. Plückthun,et al.  Miniantibodies: use of amphipathic helices to produce functional, flexibly linked dimeric FV fragments with high avidity in Escherichia coli. , 1992, Biochemistry.

[11]  W. Harris,et al.  Spontaneous assembly of bivalent single chain antibody fragments in Escherichia coli. , 1994, Molecular immunology.

[12]  K. D. Hardman,et al.  In vivo tumor targeting of a recombinant single-chain antigen-binding protein. , 1990, Journal of the National Cancer Institute.

[13]  T. Waldmann,et al.  Monoclonal antibodies in diagnosis and therapy , 1991, Science.

[14]  Jin‐Kyoo Kim,et al.  Identifying amino acid residues that influence plasma clearance of murine IgG1 fragments by site‐directed mutagenesis , 1994, European journal of immunology.

[15]  F. Buchegger,et al.  Radiolabeled fragments of monoclonal antibodies against carcinoembryonic antigen for localization of human colon carcinoma grafted into nude mice , 1983, The Journal of experimental medicine.

[16]  L L Houston,et al.  Highly specific in vivo tumor targeting by monovalent and divalent forms of 741F8 anti-c-erbB-2 single-chain Fv. , 1993, Cancer research.

[17]  P. Hand,et al.  Biological properties of chimeric domain-deleted anticarcinoma immunoglobulins. , 1995, Cancer research.

[18]  C. Gorman,et al.  Transient production of proteins using an adenovirus transformed cell line , 1990 .

[19]  A Schumitzky,et al.  A program package for simulation and parameter estimation in pharmacokinetic systems. , 1979, Computer programs in biomedicine.

[20]  E. Voss,et al.  Construction, expression, and activity of a bivalent bispecific single-chain antibody. , 1994, The Journal of biological chemistry.

[21]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[22]  S. Gillies,et al.  Serum half-life and tumor localization of a chimeric antibody deleted of the CH2 domain and directed against the disialoganglioside GD2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[23]  L E Williams,et al.  Tumor localization of anti-CEA single-chain Fvs: improved targeting by non-covalent dimers. , 1996, Immunotechnology : an international journal of immunological engineering.

[24]  U. K. Laemmli,et al.  Cleavage of Structural Proteins during the Assembly of the Head of Bacteriophage T4 , 1970, Nature.

[25]  E. Ward,et al.  Catabolism of the Murine IgGl Molecule: Evidence that Both CH2‐CH3 Domain Interfaces are Required for Persistence of IgGl in the Circulation of Mice , 1994 .

[26]  F. Buchegger,et al.  Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts. , 1993, British Journal of Cancer.

[27]  H. Huland,et al.  [Monoclonal antibodies in diagnosis and therapy]. , 1989, Immunitat und Infektion.

[28]  R. Begent,et al.  A single chain Fv derived from a filamentous phage library has distinct tumour targeting advantages over one derived from a hybridoma , 1995, International journal of cancer.

[29]  G. Winter,et al.  Comparative stabilities in vitro and in vivo of a recombinant mouse antibody FvCys fragment and a bisFvCys conjugate. , 1992, Journal of immunology.